- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00967200
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis
RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at tissue samples from patients with glioma or other brain tumors.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- To better understand the pathophysiology of gliomas and identify molecular markers that may predict prognosis and progression or that could identify new therapeutic approaches.
Secondary
- To compare gene expression profiles, in terms of response to treatment, and attempt to isolate subgroups of patients with objective response to certain types of chemotherapy or radiotherapy.
OUTLINE: This is a multicenter study.
Biological samples are collected from patients at time of surgery for diagnostic and/or treatment purposes.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- CHU Montpellier
-
Montpellier, France, 34295
- Clinique Gui de Chauliac
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Histologically confirmed glioma of any grade or rare primary brain tumor No urgent situation No known or suspected active infection Must not be deprived of liberty or protected by law Not pregnant or nursing
Exclusion :
No concurrent participation in other trials that require a period of exclusion
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathophysiology of gliomas
Time Frame: 1 day
|
Pathophysiology of gliomas that may predict prognosis and progression or that could identify new therapeutic
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of molecular
Time Frame: 1 day
|
Identification of molecular markers that may predict prognosis and progression or that could identify new therapeutic
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Luc Bauchet, MD, University Hospital, Montpellier
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- adult glioblastoma
- adult giant cell glioblastoma
- adult gliosarcoma
- recurrent adult brain tumor
- adult anaplastic astrocytoma
- adult anaplastic ependymoma
- adult anaplastic meningioma
- adult anaplastic oligodendroglioma
- adult brain stem glioma
- adult choroid plexus tumor
- adult craniopharyngioma
- adult diffuse astrocytoma
- adult ependymoblastoma
- adult ependymoma
- adult medulloblastoma
- adult meningeal hemangiopericytoma
- adult myxopapillary ependymoma
- adult oligodendroglioma
- adult papillary meningioma
- adult pineoblastoma
- adult pineocytoma
- adult subependymoma
- adult supratentorial primitive neuroectodermal tumor (PNET)
- adult grade I meningioma
- adult grade II meningioma
- adult mixed glioma
- adult pilocytic astrocytoma
- adult subependymal giant cell astrocytoma
- adult pineal gland astrocytoma
- meningeal melanocytoma
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7745 (CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Nervous System Lymphoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Central Nervous System Lymphoma | Central Nervous System B-Cell Non-Hodgkin Lymphoma | Recurrent Central Nervous System LymphomaUnited States
-
James RubensteinIncyte CorporationRecruitingPrimary Central Nervous System Lymphoma | CNS Lymphoma | Secondary Central Nervous System LymphomaUnited States
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingPrimary Central Nervous System Lymphoma | Refractory Central Nervous System Lymphoma | Relapsed Primary Central Nervous System LymphomaChina
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbActive, not recruitingPrimary Central Nervous System Lymphoma (PCNSL)United States
-
Dana-Farber Cancer InstituteRecruitingRefractory Central Nervous System Lymphoma | Central Nervous System Lymphoma | Recurrent Central Nervous System LymphomaUnited States
-
Second Affiliated Hospital, School of Medicine,...First People's Hospital of Hangzhou; First Affiliated Hospital of Zhejiang... and other collaboratorsRecruitingPrimary Central Nervous System Hodgkin LymphomaChina
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedLymphoma, Non-Hodgkin | Central Nervous System NeoplasmsNorway
-
Institut CurieNational Cancer Institute, FranceRecruitingLymphoma, Large B-Cell, Diffuse | Central Nervous System Neoplasms, PrimaryFrance
-
Ono Pharmaceutical Co. LtdRecruitingPrimary CNS Lymphoma | Refractory Primary Central Nervous System LymphomaUnited States
-
Vanderbilt-Ingram Cancer CenterBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Central Nervous System Lymphoma | Recurrent Central Nervous System LymphomaUnited States
Clinical Trials on laboratory biomarker analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed